Flozins in heart failure – a new reimbursement indication
DOI:
https://doi.org/10.56782/pps.35Keywords:
flozins, empagliflozin, dapagliflozin, diabetes, heart failureAbstract
Sodium-glucose cotransporter-2 inhibitors, called flozins, are a relatively new group of drugs that quickly have gained recognition among diabetologists, cardiologists, and nephrologists. The mechanism of their action is based on inhibition of the reabsorption of glucose inside the proximal tubule of nephron, which results in lowering a blood glucose level. In addition, flozins reduce blood pressure, cause weight loss, and reduce the risk of death from cardiovascular causes. Until recently, the potential of flozins was used only to treat patients with type 2 diabetes. The clinical trials published several years ago on three representatives of this group of drugs: dapagliflozin, empagliflozin, and canagliflozin, showed that their use in patients with type 2 diabetes and cardiovascular disease reduces the risk of hospitalization and death from cardiovascular causes. These trials prompted scientists to extend research on the effectiveness of flozins in lowering the risk of complications of heart failure and cardiovascular diseases. Subsequent studies showed that regardless of whether a patient with cardiovascular disease has diabetes, the effectiveness of empagliflozin and dapagliflozin is comparable in reducing hospitalizations and cardiovascular deaths. These discoveries resulted in flozins appearing in the European Society of Cardiology guidelines as one of the first-line drugs in heart failure with reduced ejection fraction. In Poland, empagliflozin, and dapagliflozin obtained a new reimbursement indication on May 1, 2022 – chronic heart failure with reduced ejection fraction in patients meeting specific criteria. It’s a significant step in treating heart failure, which is still a substantial cause of death and hospitalizations in Poland, especially among the aging population. The aim of this review is to show the path that flozins have gone from being an antidiabetic drug to being the first-line drug in the treatment of heart failure and to draw the attention of readers to the new reimbursement indication of flozins in Poland.
Downloads
References
Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015, 373, 2117-2128, doi:10.1056/NEJMoa1504720. DOI: https://doi.org/10.1056/NEJMoa1504720
Sjöström, C.D.; Johansson, P.; Ptaszynska, A.; List, J.; Johnsson, E. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diab Vasc Dis Res 2015, 12, 352-358, doi:10.1177/1479164115585298. DOI: https://doi.org/10.1177/1479164115585298
Neal, B.; Perkovic, V.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Erondu, N.; Shaw, W.; Law, G.; Desai, M.; Matthews, D.R. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017, 377, 644-657, doi:10.1056/NEJMoa1611925. DOI: https://doi.org/10.1056/NEJMoa1611925
Johnston, R.; Uthman, O.; Cummins, E.; Clar, C.; Royle, P.; Colquitt, J.; Tan, B.K.; Clegg, A.; Shantikumar, S.; Court, R.; et al. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2017, 21, 1-218, doi:10.3310/hta21020. DOI: https://doi.org/10.3310/hta21020
EMA. Sprawozdanie Europejskiej Agencji Leków z oceny preparatu Forxiga Available online: https://www.ema.europa.eu/en/documents/assessment-report/forxiga-epar-public-assessment-report_en.pdf. (accessed on 25.05.2022).
EMA. Sprawozdanie Europejskiej Agencji Leków z oceny preparatu Invokana. Available online: https://www.ema.europa.eu/en/documents/assessment-report/invokana-epar-public-assessment-report_en.pdf. (accessed on 25.05.2022).
EMA. Sprawozdanie Europejskiej Agencji Leków z oceny preparatu Jardiance Available online: https://www.ema.europa.eu/en/documents/assessment-report/jardiance-epar-public-assessment-report_en.pdf (accessed on 25.05.2022).
EMA. Sprawozdanie Europejskiej Agencji Leków z oceny preparatu Steglarto Available online: https://www.ema.europa.eu/en/documents/assessment-report/steglatro-epar-public-assessment-report_en.pdf (accessed on 25.05.2022).
Markham, A.; Elkinson, S. Luseogliflozin: first global approval. Drugs 2014, 74, 945-950, doi:10.1007/s40265-014-0230-8. DOI: https://doi.org/10.1007/s40265-014-0230-8
Rosenwasser, R.F.; Rosenwasser, J.N.; Sutton, D.; Choksi, R.; Epstein, B. Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc) 2014, 50, 739-745, doi:10.1358/dot.2014.50.11.2232267. DOI: https://doi.org/10.1358/dot.2014.50.11.2232267
Kashiwagi, A.; Shestakova, M.V.; Ito, Y.; Noguchi, M.; Wilpshaar, W.; Yoshida, S.; Wilding, J.P.H. Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. Diabetes Ther 2019, 10, 2201-2217, doi:10.1007/s13300-019-00699-8. DOI: https://doi.org/10.1007/s13300-019-00699-8
Markham, A. Remogliflozin Etabonate: First Global Approval. Drugs 2019, 79, 1157-1161, doi:10.1007/s40265-019-01150-9. DOI: https://doi.org/10.1007/s40265-019-01150-9
Bednarz, K.; Siuda, J. Alzheimer's disease and type 2 diabetes mellitus: similarities in pathomechanisms lead to therapeutic opportunities. Neurol Neurochir Pol 2021, 55, 418-428, doi:10.5603/PJNNS.a2021.0056. DOI: https://doi.org/10.5603/PJNNS.a2021.0056
Kautzky-Willer, A.; Harreiter, J.; Pacini, G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocr Rev 2016, 37, 278-316, doi:10.1210/er.2015-1137. DOI: https://doi.org/10.1210/er.2015-1137
Araszkiewicz, A.; Bandurska-Stankiewicz, E.; Borys, S.; Budzyński, A.; Cyganek, K.; Cypryk, K.; Czech, A.; Czupryniak, L.; Drzewoski, J.; Dzida, G.; et al. 2021 Guidelines on the management of patients with diabetes. A position of Diabetes Poland. Clinical Diabetology 2021, 10, 1-113, doi:10.5603/dk.2021.0001. DOI: https://doi.org/10.5603/DK.2021.0001
Cosentino, F.; Grant, P.J.; Aboyans, V.; Bailey, C.J.; Ceriello, A.; Delgado, V.; Federici, M.; Filippatos, G.; Grobbee, D.E.; Han-sen, T.B.; et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020, 41, 255-323, doi:10.1093/eurheartj/ehz486. DOI: https://doi.org/10.1093/eurheartj/ehz486
Kałużna-Oleksy, M. Niewydolność serca w Polsce - Realia, koszty, sugestie poprawy sytuacji; Porozumienie Organizacji Kar-diologicznych – Razem dla Serca: 2020.
Disease, G.B.D.; Injury, I.; Prevalence, C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017, 390, 1211-1259, doi:10.1016/S0140-6736(17)32154-2. DOI: https://doi.org/10.1016/S0140-6736(17)32154-2
Nessler, J.; Siniarski, A.; Leszek, P.; Gumprecht, J.; Drożdż, J.; Kaźmierczak, J.; Witkowski, A.; Gackowski, A.; Jankowska, E.A.; Kukulski, T.; et al. Zastosowanie dapagliflozyny w leczeniu niewydolności serca ze zmniejszoną frakcją wyrzutową lewej komory. Kar-diologia Polska (Polish Heart Journal) 2021, 79, 143-151. DOI: https://doi.org/10.33963/KP.15859
Nessler, J.; Kozierkiewicz, A.; Gackowski, A.; Ponikowski, P.; Hryniewiecki, T.; Gruchała, M.; Gąsior, M.; Grodzicki, T.; Kaź-mierczak, J.; Legutko, J.; et al. Comprehensive Heart Failure Care pilot study: starting point and expected developments. Kardiol Pol 2019, 77, 994-999, doi:10.33963/kp.15035. DOI: https://doi.org/10.33963/KP.15035
Wiviott, S.D.; Raz, I.; Bonaca, M.P.; Mosenzon, O.; Kato, E.T.; Cahn, A.; Silverman, M.G.; Zelniker, T.A.; Kuder, J.F.; Murphy, S.A.; et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019, 380, 347-357, doi:10.1056/NEJMoa1812389. DOI: https://doi.org/10.1056/NEJMoa1812389
Kluger, A.Y.; Tecson, K.M.; Barbin, C.M.; Lee, A.Y.; Lerma, E.V.; Rosol, Z.P.; Rangaswami, J.; Lepor, N.E.; Cobble, M.E.; McCullough, P.A. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review. Rev Cardiovasc Med 2018, 19, 41-49, doi:10.31083/j.rcm.2018.02.907. DOI: https://doi.org/10.31083/j.rcm.2018.02.907
McMurray, J.J.V.; Solomon, S.D.; Inzucchi, S.E.; Køber, L.; Kosiborod, M.N.; Martinez, F.A.; Ponikowski, P.; Sabatine, M.S.; Anand, I.S.; Bělohlávek, J.; et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019, 381, 1995-2008, doi:10.1056/NEJMoa1911303. DOI: https://doi.org/10.1056/NEJMoa1911303
Packer, M.; Anker, S.D.; Butler, J.; Filippatos, G.; Pocock, S.J.; Carson, P.; Januzzi, J.; Verma, S.; Tsutsui, H.; Brueckmann, M.; et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020, 383, 1413-1424, doi:10.1056/NEJMoa2022190. DOI: https://doi.org/10.1056/NEJMoa2022190
McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O.; et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021, 42, 3599-3726, doi:10.1093/eurheartj/ehab368. DOI: https://doi.org/10.1093/eurheartj/ehab368
FDA. Komunikat prasowy FDA dotyczący zatweirdzenia Dapagliflozyny w leczeniu HFrEF. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-type-heart-failure (accessed on 25.05.2022).
Anker, S.D.; Butler, J.; Filippatos, G.; Ferreira, J.P.; Bocchi, E.; Böhm, M.; Brunner-La Rocca, H.P.; Choi, D.J.; Chopra, V.; Chuquiure-Valenzuela, E.; et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021, 385, 1451-1461, doi:10.1056/NEJMoa2107038. DOI: https://doi.org/10.1056/NEJMoa2107038
FDA. Komunikat prasowy FDA dotyczący zatwierdzenia empagliflozyny u pacjentów w HFpEF. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-wider-range-patients-heart-failure (accessed on 25.05.2022).
Obwieszczenie Ministra Zdrowia z dnia 20 kwietnia 2022 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 maja 2022 r. Available online: https://www.gov.pl/web/zdrowie/obwieszczenie-ministra-zdrowia-z-dnia-20-kwietnia-2022-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych-na-1-maja-2022-r (accessed on 25.05.2022).
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
